Abivax Shares Climb 2.41% at Midday this Tuesday, December 31

Abivax shares are up 2.41% this Tuesday, December 31 at midday, bringing the price to 118.80 euros from 116.00 euros the day before. Trading volumes remain limited with only 0.02% of the capital traded in this last session of the year. This slight increase is part of a context of moderate volatility following the recent upward trend, marked by a weekly performance of -0.83% indicating a consolidation phase. Over the past quarter, the French biotech has maintained a spectacular increase of 67.56%, while the annual performance has reached 1,673%, confirming its status as the best stock market performance in Europe in 2025. The stock is now well above its moving averages, with a price 70.25 euros above the 50-day moving average set at 97.65 euros, and a significant gap of 70.25 euros compared to the 200-day moving average positioned at 48.55 euros. This chart configuration illustrates the exceptional magnitude of the stock's revaluation since the beginning of the year.

According to the media outlet La Lettre, a delegation from Eli Lilly visited the French Treasury Directorate on December 10 to submit a takeover bid of Abivax for a preliminary test of foreign investment controls in France. The Ministry of Economy stated it is 'closely monitoring' the Abivax file, adding that 'verifications are underway'. These revelations have fueled market speculation, although no official confirmation has been provided by the involved parties. Meanwhile, on December 18, 2025, Abivax announced its inclusion in the Nasdaq Biotechnology Index effective December 22, 2025, enhancing its visibility among international institutional investors. This inclusion reflects the recognition of the commercial potential of obezafimod, its drug candidate for ulcerative colitis. In July, the company had published very positive results from phase III clinical trials, a major catalyst for the stock's soaring performance. Analysts maintain constructive price targets, with Truist Securities aiming for 140 euros, Piper Sandler at 142 euros, and Wolfe Research setting an ambitious target at 176 dollars.

The RSI shows a level of 61 at midday, returning to a more neutral zone after reaching overbought levels above 70 in previous sessions. This moderation of the indicator suggests that buying pressure has somewhat eased, allowing the stock to consolidate its recent gains. The MACD histogram remains positive at 1.59, with a MACD line at 4.73 above its signal line at 3.14, confirming that the upward momentum remains intact in the short term despite the pause observed this week. The Bollinger Bands currently frame the stock between 86.53 euros and 125.66 euros, with the price of 118.80 euros positioned in the upper part of this range without crossing the upper bound. This position reflects a controlled extension of the upward movement, after the excesses observed in previous sessions where the price was moving beyond statistical limits. The support threshold identified at 93.30 euros serves as a reference point in case of correction, while the resistance at 122.40 euros represents the level to overcome to reignite the upward momentum. With a cash reserve of 589.7 million euros as of September 30, 2025, the company has financial autonomy until the fourth quarter of 2027, allowing it to confidently continue its clinical programs with maintenance results expected in the second quarter of 2026.